Healthcare Giant Johnson & Johnson Sets Sights on New Milestones
Published on 10/07/2025 at 16:00 | Redaktion boerse-global.de
Johnson & Johnson is demonstrating remarkable momentum on dual fronts. The healthcare conglomerate’s shares are approaching a fresh annual peak, bolstered by promising clinical trial outcomes for a novel psoriasis treatment. The critical question now emerges: can this pharmaceutical leader sustain its upward trajectory?
The positive sentiment surrounding Johnson & Johnson is clearly reflected in recent analyst actions. Several prominent financial institutions have significantly revised their outlooks:
- Bernstein lifted its price target from $172 to $193.
- Wells Fargo upgraded the stock from “Hold” to “Buy,” establishing a $212 target.
- BofA Securities followed suit, raising its projection to $198.
This wave of confidence propelled the share price... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
